The new world of poly-(ADP)-ribose polymerase inhibitors (PARPi) used in the treatment of gynecological cancers

The clinical development of poly-(ADP)-ribose polymerase inhibitors (PARPi) began with the treatment of ovarian cancer patients harboring BRCA1/2 mutations and continues to be expanded to other gynecological cancers. Furthermore, The Cancer Genome Atlas (TCGA) analysis of endometrial and cervical ca...

Full description

Saved in:
Bibliographic Details
Published inInternational journal of gynecological cancer Vol. 30; no. 10; pp. 1608 - 1618
Main Authors Chelariu-Raicu, Anca, Zibetti Dal Molin, Graziela, Coleman, Robert L
Format Journal Article
LanguageEnglish
Published England BMJ Publishing Group LTD 01.10.2020
Subjects
Biomarkers
Cervical cancer
Endometrial cancer
Gynecological cancer
Kinases
Mutation
Ovarian cancer
Uterine cancer
BRCA2 protein
BRCA1 protein
homologous recombination
ovarian cancer
uterine cancer
Online AccessGet full text

Cover

More Information
Summary:The clinical development of poly-(ADP)-ribose polymerase inhibitors (PARPi) began with the treatment of ovarian cancer patients harboring BRCA1/2 mutations and continues to be expanded to other gynecological cancers. Furthermore, The Cancer Genome Atlas (TCGA) analysis of endometrial and cervical cancers offered rationale that PARPi may be an option for treatment based on the molecular profiles of these cancer types. This review summarizes the current indications of PARPi, such as its role in the treatment and maintenance of recurrent ovarian cancer and for first-line maintenance therapy in advanced ovarian cancer. We also outline new concepts for PARPi therapy in other gynecological cancers such as endometrial and cervical cancers based on recent clinical data. Finally, we present potential future directions to continue exploring the world of PARPi resistance and combining PARPi with other therapies.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:1048-891X
1525-1438
DOI:10.1136/ijgc-2020-001789